No association of polymorphisms in the gene encoding 5-lipoxygenase- activating protein and myocardial infarction in a large central European population

Genetics in Medicine

Volumn 9, Issue 2, 2007, Pages 123-129

  Koch, Werner ^a   Hoppmann, Petra ^a   Mueller, Jakob C ^b   Schömig, Albert ^a   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MAX PLANCK INSTITUTE FOR ORNITHOLOGY   (Germany)

Author keywords

5 lipoxygenase activating protein (FLAP); ALOX5AP; Genetics; Haplotype; Myocardial infarction

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN;

ADULT; ALLELE; ARTICLE; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY; DNA POLYMORPHISM; EUROPE; FEMALE; GENOTYPE; HAPLOTYPE; HEART INFARCTION; HUMAN; ICELAND; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NUCLEOTIDE SEQUENCE; RISK; UNITED KINGDOM;

AGED; CARRIER PROTEINS; CASE-CONTROL STUDIES; DNA PRIMERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERMANY; HAPLOTYPES; HUMANS; LOGISTIC MODELS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33847072582     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e318030c9c5     Document Type: Article

References (22)

1. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004;36:233-239.
2. Kajimoto K, Shioji K, Ishida C, Iwanaga Y, et al. Validation of the association between the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a Japanese population. Circ J 2005;69:1029-1034.
3. Helgadottir A, Gretarsdottir S, St. Clair D, Manolescu A, et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 2005;76:505-509.
4. Lõhmussaar E, Gschwendtner A, Mueller JC, Org T, et al. ALOX5AP gene and the PDE4D gene in a Central European population of stroke patients. Stroke 2005;36:731-736.
5. Miller DK, Gillard JW, Vickers PJ, Sadowski S, et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990;343:278-281.
6. Dixon RAF, Diehl RE, Opas E, Rands E, et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990;343:282-284.
7. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
8. Dwyer JH, Allayee H, Dwyer KM, Fan J, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004;350:29-37.
9. De Caterina R, Zampolli A. From asthma to atherosclerosis - 5-lipoxygenase, leukotrienes, and inflammation. N Engl J Med 2004;350:4-7.
10. Spanbroek R, Gräbner R, Lötzer K, Hildner M, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A 2003;100:1238-1243.
11. Zhao L, Funk CD. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc Med 2004;14:191-195.
12. Kennedy BP, Diehl RE, Boie Y, Adam M, et al. Gene characterization and promoter analysis of the human 5-lipoxygenase-activating protein (FLAP). J Biol Chem 1991;266:8511-8516.
13. Yandava CN, Kennedy BP, Pillari A, Duncan AM, et al. Cytogenetic and radiation hybrid mapping of human arachidonate 5-lipoxygenase-activating protein (ALOX5AP) to chromosome 13q12. Genomics 1999;56:131-133.
14. Zee RYL, Cheng S, Hegener HH, Erlich HA, et al. Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke. A nested case-control approach. Stroke 2006;37:2007-2011.
15. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925-926.
16. Chalmers J, MacMahon S, Mancia G, Whitworth J, et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 1999;21:1009-1060.
17. Diabetes mellitus. World Health Organization Study Group. Diabetes mellitus. WHO Tech Rep Ser 1985;727:1-104.
18. Kutyavin IV, Afonina IA, Mills A, Gorn VV, et al. 3′-Minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures. Nucleic Acids Res 2000;28:655-661.
19. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-989.
20. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering committee of the Physicians' Health Study research group. N Engl J Med 1989;321:129-135.
21. Ioannidis JPA, Ntzani EE, Trikalinos TA. 'Racial' differences in genetic effects for complex diseases. Nat Genet 2004;36:1312-1318.
22. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002;4:45-61.